U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06903923) titled 'Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy' on March 25.
Brief Summary: The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management.
Participants will:
* Take Semaglutide as prescribed or continue to work on lifestyle management for weight loss
* Take provided calcium and vitamin D supplements
* Attend 6 study visits over 24 months with two at the beginning and then every 6 months that inc...